APLM
Price:
$0.1147
Market Cap:
$12.46M
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated...[Read more]
Industry
Biotechnology
IPO Date
2021-11-26
Stock Exchange
NASDAQ
Ticker
APLM
According to Apollomics, Inc.’s latest financial reports and current stock price. The company's current ROE is -184.11%. This represents a change of 231.24% compared to the average of -55.58% of the last 4 quarters.
The mean historical ROE of Apollomics, Inc. over the last ten years is -37.25%. The current -184.11% ROE has changed 394.31% with respect to the historical average. Over the past ten years (40 quarters), APLM's ROE was at its highest in in the December 2022 quarter at 26.49%. The ROE was at its lowest in in the September 2021 quarter at -73842.06%.
Average
-37.25%
Median
53.74%
Minimum
-418.59%
Maximum
75.60%
Discovering the peaks and valleys of Apollomics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 20.67%
Maximum Annual ROE = 75.60%
Minimum Annual Increase = -878.94%
Minimum Annual ROE = -418.59%
Year | ROE | Change |
---|---|---|
2023 | -418.59% | -878.94% |
2022 | 53.74% | 20.67% |
2021 | 44.53% | -23.85% |
2020 | 58.48% | -22.64% |
The current ROE of Apollomics, Inc. (APLM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-106.77%
5-year avg
-37.25%
10-year avg
-37.25%
Apollomics, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apollomics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Apollomics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Apollomics, Inc.'s ROE?
How is the ROE calculated for Apollomics, Inc. (APLM)?
What is the highest ROE for Apollomics, Inc. (APLM)?
What is the 3-year average ROE for Apollomics, Inc. (APLM)?
What is the 5-year average ROE for Apollomics, Inc. (APLM)?
How does the current ROE for Apollomics, Inc. (APLM) compare to its historical average?